M. Kraus & Co Has $8.89 Million Stake in Abbott Laboratories (NYSE:ABT)

M. Kraus & Co boosted its position in shares of Abbott Laboratories (NYSE:ABTGet Rating) by 0.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 81,854 shares of the healthcare product maker’s stock after buying an additional 207 shares during the period. Abbott Laboratories makes up approximately 3.4% of M. Kraus & Co’s investment portfolio, making the stock its 12th largest position. M. Kraus & Co’s holdings in Abbott Laboratories were worth $8,893,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Norges Bank bought a new position in shares of Abbott Laboratories in the fourth quarter worth about $2,290,723,000. Jennison Associates LLC raised its holdings in Abbott Laboratories by 240.8% in the 1st quarter. Jennison Associates LLC now owns 6,052,143 shares of the healthcare product maker’s stock valued at $716,332,000 after buying an additional 4,276,374 shares during the last quarter. BlackRock Inc. raised its holdings in Abbott Laboratories by 2.1% in the 4th quarter. BlackRock Inc. now owns 137,155,602 shares of the healthcare product maker’s stock valued at $19,303,283,000 after buying an additional 2,836,966 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Abbott Laboratories by 83.1% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 4,925,012 shares of the healthcare product maker’s stock valued at $582,924,000 after buying an additional 2,235,314 shares during the last quarter. Finally, Vanguard Group Inc. raised its holdings in Abbott Laboratories by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 151,288,441 shares of the healthcare product maker’s stock valued at $17,906,500,000 after buying an additional 2,136,177 shares during the last quarter. 73.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Abbott Laboratories

In related news, SVP Fernando Mateus sold 2,457 shares of the company’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $109.05, for a total transaction of $267,935.85. Following the completion of the transaction, the senior vice president now owns 14,503 shares in the company, valued at $1,581,552.15. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Robert B. Ford sold 102,425 shares of the stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $105.10, for a total value of $10,764,867.50. Following the sale, the chief executive officer now directly owns 142,071 shares of the company’s stock, valued at $14,931,662.10. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Fernando Mateus sold 2,457 shares of the stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $109.05, for a total value of $267,935.85. Following the sale, the senior vice president now directly owns 14,503 shares in the company, valued at $1,581,552.15. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 204,788 shares of company stock worth $21,776,756. 0.52% of the stock is currently owned by insiders.

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded down $1.68 during mid-day trading on Friday, reaching $99.39. 373,736 shares of the company’s stock were exchanged, compared to its average volume of 4,955,861. The firm has a market capitalization of $174.05 billion, a price-to-earnings ratio of 21.10, a price-to-earnings-growth ratio of 3.73 and a beta of 0.72. Abbott Laboratories has a 52 week low of $99.85 and a 52 week high of $142.60. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.01 and a quick ratio of 1.54. The firm has a 50-day moving average price of $107.10 and a two-hundred day moving average price of $111.67.

Abbott Laboratories (NYSE:ABTGet Rating) last posted its earnings results on Wednesday, July 20th. The healthcare product maker reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.34. The business had revenue of $11.26 billion during the quarter, compared to analyst estimates of $10.37 billion. Abbott Laboratories had a return on equity of 29.38% and a net margin of 18.78%. The company’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.17 EPS. Analysts predict that Abbott Laboratories will post 4.99 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, November 15th. Shareholders of record on Friday, October 14th will be paid a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 1.89%. The ex-dividend date is Thursday, October 13th. Abbott Laboratories’s dividend payout ratio is currently 39.25%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ABT shares. BTIG Research dropped their price objective on shares of Abbott Laboratories from $130.00 to $126.00 and set a “buy” rating for the company in a report on Monday, July 18th. StockNews.com upgraded shares of Abbott Laboratories from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 3rd. Erste Group Bank lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Thursday, August 25th. Evercore ISI lowered their price target on shares of Abbott Laboratories to $112.00 in a report on Friday, July 22nd. Finally, Wolfe Research assumed coverage on shares of Abbott Laboratories in a report on Tuesday, July 5th. They set an “underperform” rating for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $132.46.

Abbott Laboratories Company Profile

(Get Rating)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Further Reading

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.